1. Home
  2. News Archive

More News

Mallinckrodt Spins Off Generics Business, Rebrands as Keenova
Mallinckrodt Spins Off Generics Business, Rebrands as Keenova

Drugmaker Mallinckrodt announced Nov. 10 that it had completed the planned spinoff of its Par Health generic pharmaceuticals and sterile injectables businesses and had rebranded as Keenova Therapeu...

Numerous New Products Showcased at 2025 AAO Meeting
Numerous New Products Showcased at 2025 AAO Meeting

More than 16 thousand people attended the 2025 meeting of the American Academy of Ophthalmology, held Oct. 17-20 at the Orange County Convention Center in Orlando, Florida. Sixty percent of them we...

Interest Builds for Presbyopia Drops, as Third Therapy Hits Market
Interest Builds for Presbyopia Drops, as Third Therapy Hits Market

Lenz Therapeutics’ newly launched Vizz was met with enthusiasm at the 2025 meeting of the 2025 AAO meeting, as attendees crowded the company’s large booth. Lenz made Vizz available commercially in ...

AAO Speakers Continue to Promote Glaucoma Laser Innovation and Effectiveness
AAO Speakers Continue to Promote Glaucoma Laser Innovation and Effectiveness

The 2025 AAO meeting underscored the importance of laser therapy in glaucoma and highlighted emerging technology that aims to shape the future of the market. Selective laser trabeculoplasty (SLT) t...

2025-2027 Ophthalmic Meetings Calendar
2025-2027 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

How Two CMS Cuts Affect Final 2026 Physician Fee Schedule
How Two CMS Cuts Affect Final 2026 Physician Fee Schedule

Two reductions to parts of the formula used to calculate physicians’ Medicare procedure fees in 2026 are lowering reimbursement significantly for common ophthalmic procedures. The formula involves ...

Novartis Offloads Rights to Beovu, Lucentis in South Korea, China
Novartis Offloads Rights to Beovu, Lucentis in South Korea, China

Swiss drugmaker Novartis made deals in October to offload distribution rights to retinal treatments Beovu (brolucizumab) and Lucentis (ranibizumab) in South Korea and mainland China. Japan’s Santen...

Clinical Trial Updates for Ophthalmic Candidates, November 2025
Clinical Trial Updates for Ophthalmic Candidates, November 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

US FDA Rejects Sydnexis’ Low-Dose Atropine Drop for Pediatric Myopia
US FDA Rejects Sydnexis’ Low-Dose Atropine Drop for Pediatric Myopia

Sydnexis announced Oct. 23 that the US FDA had issued a complete response letter rejecting the company’s new drug application (NDA) for SYD-101, a low-dose atropine formulation to slow the progress...

Richard Pazdur, MD, to Lead US FDA’s Center for Drug Evaluation and Research
Richard Pazdur, MD, to Lead US FDA’s Center for Drug Evaluation and Research

The US FDA reported Nov. 11 that oncologist Richard Pazdur, MD, had been named director of the Center for Drug Evaluation and Research (CDER). Pazdur is a 26-year veteran of the FDA and the foundin...

Weekly Ophthalmologist and Optometrist Poll, November 2025
Weekly Ophthalmologist and Optometrist Poll, November 2025

November 2025 Ophthalmic News Briefs
November 2025 Ophthalmic News Briefs

VEO Ophthalmics announced Oct. 16 that the VisionOne VR Visual Field platform is now available in the US through a strategic partnership with Switzerland’s PeriVision. No financial details about th...

UK High Court Ruling Paves Way for Launch of Alvotech’s Aflibercept Biosimilar
UK High Court Ruling Paves Way for Launch of Alvotech’s Aflibercept Biosimilar

Iceland’s Alvotech announced Nov. 10 that the UK High Court had rejected an injunction from Eylea marketers Regeneron and Bayer against Alvotech and its contract manufacturing organization. The dec...

FDA Clears Way for US Patient to Receive GenSight’s Lumevoq for LHON
FDA Clears Way for US Patient to Receive GenSight’s Lumevoq for LHON

France’s GenSight Biologics announced Oct. 30 that the FDA had granted permission for a single patient in the US to be treated with GS010, also known as Lumevoq, GenSight’s intravitreal gene therap...

Emerging Companies Pursuing Ophthalmic Indications, November 2025
Emerging Companies Pursuing Ophthalmic Indications, November 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Lilly, MeiraGTx Sign Ophthalmic Gene Therapy Deal Worth Up to $475 Million
Lilly, MeiraGTx Sign Ophthalmic Gene Therapy Deal Worth Up to $475 Million

MeiraGTx Holdings announced Nov. 10 that it granted drugmaker Eli Lilly exclusive worldwide rights to its AAV-AIPL1 gene therapy program targeting Leber congenital amaurosis 4 (LCA4). Lilly will al...

Q3-2025 Ophthalmic Revenue Roundup for Alcon, Santen, Immunocore, STAAR, Harrow, and Five Others
Q3-2025 Ophthalmic Revenue Roundup for Alcon, Santen, Immunocore, STAAR, Harrow, and Five Others

Alcon reported Nov. 11 that its Q3-2025 net sales totaled $2.6 billion, a 6 percent increase over $2.4 billion in Q3-2024. Surgical net sales for implantables, consumables, and equipment/other were...

Sydnexis Gains UK Approval for Low-Dose Atropine Drops in Pediatric Myopia
Sydnexis Gains UK Approval for Low-Dose Atropine Drops in Pediatric Myopia

Sydnexis announced Nov. 6 that the UK’s Medicines and Healthcare Products Regulatory Agency had granted marketing authorization for Ryjunea, the company’s low-dose atropine formulation for slowing ...

STAAR Solicits New Bids Under Amended Deal with Alcon, Moves Shareholder Vote to Dec. 19
STAAR Solicits New Bids Under Amended Deal with Alcon, Moves Shareholder Vote to Dec. 19

STAAR Surgical reported Nov. 7 that it had amended its merger agreement with Alcon to allow STAAR to solicit new buyers for 30 days under a new “go-shop” period ending Dec. 6. STAAR also delayed to...

Richard Pazdur, MD, to Lead US FDA’s Center for Drug Evaluation and Research
Richard Pazdur, MD, to Lead US FDA’s Center for Drug Evaluation and Research

The US FDA reported Nov. 11 that oncologist Richard Pazdur, MD, had been named director of the Center for Drug Evaluation and Research (CDER). Pazdur is a 26-year veteran of the FDA and the foundin...

UK High Court Ruling Paves Way for Launch of Alvotech’s Aflibercept Biosimilar
UK High Court Ruling Paves Way for Launch of Alvotech’s Aflibercept Biosimilar

Iceland’s Alvotech announced Nov. 10 that the UK High Court had rejected an injunction from Eylea marketers Regeneron and Bayer against Alvotech and its contract manufacturing organization. The dec...

Kwangdong Submits NDA in South Korea for Tenpoint’s Presbyopia Drop
Kwangdong Submits NDA in South Korea for Tenpoint’s Presbyopia Drop

Tenpoint Therapeutics announced Nov. 5 that Kwangdong Pharmaceutical had submitted a new drug application (NDA) to the Ministry of Food and Drug Safety in South Korea for Brimochol PF, a combinatio...

Mallinckrodt Spins Off Generics Business, Rebrands as Keenova
Mallinckrodt Spins Off Generics Business, Rebrands as Keenova

Drugmaker Mallinckrodt announced Nov. 10 that it had completed the planned spinoff of its Par Health generic pharmaceuticals and sterile injectables businesses and had rebranded as Keenova Therapeu...

PolyActiva, RareSight to Collaborate on Rare Pediatric Retinal Diseases
PolyActiva, RareSight to Collaborate on Rare Pediatric Retinal Diseases

Australia’s PolyActiva announced Nov. 5 that it would collaborate with RareSight, of Menlo Park, California, an ophthalmology-focused life sciences company committed to advancing therapies for rare...

CMS’ Changes to Final 2026 Physician Fee Schedule Include Two Significant Cuts
CMS’ Changes to Final 2026 Physician Fee Schedule Include Two Significant Cuts

The Centers for Medicare and Medicaid Services (CMS) made two significant cuts to parts of the formula used to calculate physicians’ Medicare procedure fees in 2026, despite heavy lobbying by the m...

Viridian Submits BLA to US FDA for Veligrotug in Thyroid Eye Disease
Viridian Submits BLA to US FDA for Veligrotug in Thyroid Eye Disease

Viridian Therapeutics announced Nov. 3 that it had submitted a biologics license application (BLA) to the US FDA for veligrotug, the company’s intravenous treatment candidate for thyroid eye diseas...

4DMT Licenses Retinal Gene Therapy Candidate to Otsuka for Asia-Pacific
4DMT Licenses Retinal Gene Therapy Candidate to Otsuka for Asia-Pacific

4D Molecular Therapeutics announced Oct. 30 a strategic partnership with Otsuka Pharmaceutical Co. to develop and commercialize retinal gene therapy candidate 4D-150 in the greater Asia-Pacific (AP...

Q3-2025 Ophthalmic Revenue Roundup for Amgen, AbbVie, Hoya, Glaukos, Apellis, Astellas, and Four Others
Q3-2025 Ophthalmic Revenue Roundup for Amgen, AbbVie, Hoya, Glaukos, Apellis, Astellas, and Four Others

Amgen, of Thousand Oaks, California, reported Nov. 4 that its Q3-2025 revenue from Tepezza was $560 million, a 15 percent increase over $488 million in Q3-2024. The total consisted of $518 million ...

Samsung Bioepis to Commercialize Byooviz in Europe Starting in January 2026
Samsung Bioepis to Commercialize Byooviz in Europe Starting in January 2026

South Korea’s Samsung Bioepis announced Oct. 29 that it would assume responsibility for the marketing of Byooviz (ranibizumab), a Lucentis biosimilar, in Europe upon the transfer of commercial righ...

UK Accepts Conditional Marketing Application for Belite Bio’s Tinlarebant in Stargardt
UK Accepts Conditional Marketing Application for Belite Bio’s Tinlarebant in Stargardt

Belite Bio announced Nov. 2 that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) had agreed to accept a conditional marketing authorization application for oral tinlarebant for ...

FDA Clears Way for US Patient to Receive GenSight’s Lumevoq for LHON
FDA Clears Way for US Patient to Receive GenSight’s Lumevoq for LHON

France’s GenSight Biologics announced Oct. 30 that the FDA had granted permission for a single patient in the US to be treated with GS010, also known as Lumevoq, GenSight’s intravitreal gene therap...

Outlook Resubmits BLA to US FDA for Ophthalmic Bevacizumab (Lytenava)
Outlook Resubmits BLA to US FDA for Ophthalmic Bevacizumab (Lytenava)

Outlook Therapeutics reported Nov. 3 that it had resubmitted its biologics license application (BLA) to the US FDA for ONS-5010 (Lytenava), an ophthalmic formulation of bevacizumab for wet age-rela...

Visara Licenses Retinal Candidate to Everest for Greater China, Other Asian Countries
Visara Licenses Retinal Candidate to Everest for Greater China, Other Asian Countries

NovaBridge Biosciences announced Oct. 29 that its ophthalmic subsidiary, Visara, had licensed retinal treatment candidate VIS-101 to Everest Medicines for greater China, Singapore, South Korea, and...

Roche Reports Mixed Phase III Data for Vamikibart in Uveitic Macular Edema
Roche Reports Mixed Phase III Data for Vamikibart in Uveitic Macular Edema

Swiss drugmaker Roche reported on Oct. 16 mixed Phase III results for vamikibart, an IL-6 inhibitor being developed to address inflammation in uveitic macular edema (UME). Vamikibart, if approved, ...

US FDA Rejects Sydnexis’ Atropine Drop for Pediatric Myopia
US FDA Rejects Sydnexis’ Atropine Drop for Pediatric Myopia

Sydnexis announced Oct. 23 that the US FDA had issued a complete response letter rejecting the company’s new drug application (NDA) for SYD-101, a low-dose atropine formulation to slow the progress...

Lilly to Acquire Adverum in Deal Worth Up to $262 Million
Lilly to Acquire Adverum in Deal Worth Up to $262 Million

Drugmaker Eli Lilly announced Oct. 24 that it would acquire Adverum Biotechnologies, developer of Ixo-vec, a Phase III intravitreal gene therapy candidate targeting wet age-related macular degenera...

STAAR Moves Shareholder Vote on Alcon Acquisition to Dec. 3
STAAR Moves Shareholder Vote on Alcon Acquisition to Dec. 3

STAAR Surgical on Oct. 27 postponed until Dec. 3 its special meeting of shareholders to vote on Alcon’s acquisition of the company. STAAR also set a new record date of Oct. 24. Stockholders who hel...

Q3-2025 Ophthalmic Revenue Roundup for Bausch + Lomb,  Roche, Regeneron, Novartis
Q3-2025 Ophthalmic Revenue Roundup for Bausch + Lomb,  Roche, Regeneron, Novartis

Bausch + Lomb reported Oct. 29 that its Q3-2025 revenue totaled $1.3 billion, a 7 percent increase over $1.2 billion in Q3-2024. Ophthalmic pharmaceuticals segment revenue was $330 million, an 8 pe...

US FDA Again Rejects Xbrane’s Ranibizumab Biosimilar Candidate
US FDA Again Rejects Xbrane’s Ranibizumab Biosimilar Candidate

Sweden’s Xbrane Biopharma announced Oct. 19 that the US FDA had issued a complete response letter rejecting the company’s resubmitted biologics license application (BLA) for its Lucentis (ranibizum...

US FDA Rejects Eylea HD Prefilled Syringe over Inspection at Catalent Site
US FDA Rejects Eylea HD Prefilled Syringe over Inspection at Catalent Site

Regeneron reported in its Q3-2025 results on Oct. 28 that the US FDA had issued a complete response letter rejecting the supplemental biologics license application (sBLA) for a prefilled syringe of...

China Medical System Acquires Rights in China to Novartis’ Beovu and Lucentis
China Medical System Acquires Rights in China to Novartis’ Beovu and Lucentis

China Medical System Holdings of Hong Kong announced Oct. 27 that its ophthalmic subsidiary CMS Vision had acquired exclusive distribution rights in mainland China for Novartis’ retinal treatments ...

Amsurg Acquires ASC in South Carolina, Expanding Footprint in State
Amsurg Acquires ASC in South Carolina, Expanding Footprint in State

Amsurg, of Nashville, Tennessee, reported Oct. 28 that it had acquired Surgery Center of Conway, in Conway, South Carolina, its fourth center in the state. Amsurg, a leader in ambulatory surgery ce...

Viatris, Locus Biosciences to Collaborate on Ophthalmic Antibacterial Therapies
Viatris, Locus Biosciences to Collaborate on Ophthalmic Antibacterial Therapies

Viatris and Locus Biosciences announced on Oct. 28 a research collaboration to develop novel products targeting ophthalmic bacterial infections. No financial details about the collaboration were di...

VEO Ophthalmics Launches PeriVision’s VisionOne VR Visual Field Platform in US
VEO Ophthalmics Launches PeriVision’s VisionOne VR Visual Field Platform in US

VEO Ophthalmics announced Oct. 16 that the VisionOne VR Visual Field platform is now available in the US through a strategic partnership with Switzerland’s PeriVision. No financial details about th...

Alcon-STAAR Deal Up in the Air as Shareholder Vote is Delayed
Alcon-STAAR Deal Up in the Air as Shareholder Vote is Delayed

STAAR Surgical adjourned until Nov. 6 the shareholder vote for its planned sale to Alcon during a virtual special meeting of shareholders on Oct. 23. Alcon made public on Aug. 5 its plans to purcha...

US FDA Approves Glaukos’ Epioxa Epi-On Crosslinking Therapy for Keratoconus
US FDA Approves Glaukos’ Epioxa Epi-On Crosslinking Therapy for Keratoconus

Glaukos, of Aliso Viejo, California, reported Oct. 20 that the US FDA had approved Epioxa, an epi-on version of the company’s iLink corneal crosslinking therapy for keratoconus. Thomas Burns, Glauk...

J&J Vision Surgical Posts Q3-2025 Revenue of $383 Million
J&J Vision Surgical Posts Q3-2025 Revenue of $383 Million

J&J Vision’s Q3-2025 global surgical vision revenue totaled $383 million, a 14.9 percent increase over $333 million in Q3-2024, parent Johnson & Johnson, of New Brunswick, New Jersey, reported Oct....

2025 ESCRS Congress Boasts Strong Attendance and Multiple Product Launches
2025 ESCRS Congress Boasts Strong Attendance and Multiple Product Launches

More than 15 thousand people registered for the 2025 congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held Sept. 12-16 at the Bella Center in Copenhagen, Denmark. Sixty...

Topcon Healthcare to Acquire AI Screening Company Toku
Topcon Healthcare to Acquire AI Screening Company Toku

Topcon Healthcare announced Oct. 17 that it had signed a definitive agreement to acquire Toku, an artificial intelligence (AI) health technology company originally founded in New Zealand. No financ...

Santen Acquires Rights in South Korea to Novartis’ Beovu and Lucentis
Santen Acquires Rights in South Korea to Novartis’ Beovu and Lucentis

Santen Pharmaceutical announced Oct. 20 that it had acquired exclusive distribution rights in South Korea for Novartis’ retinal treatments Beovu (brolucizumab) and Lucentis (ranibizumab). Both Beov...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more